Search Result

Search Result

Isoforms Recommended:	PAC1 Receptor

Results for "

PAC1 receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (1) Apoptosis (1) Calcium Channel (2) Caspase (1) EGFR (2) ERK (2) Interleukin Related (1) PACAP Receptor (7) PKA (1) Reactive Oxygen Species (ROS) (2) TNF Receptor (1)
By Research Areas:	Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (10)

10

Inhibitors & Agonists

5

Peptides

2

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

PA-915 1 Publications Verification PAC1R antagonist 1	PACAP Receptor	Neurological Disease
PA-915 (PAC1R antagonist 1) (compound 3d) is a potent and orally active antagonist of **PAC1 receptor*. PAC1*R antagonist 1 can inhibit pituitary adenylate cyclase-activating polypeptide (PACAP)- and nerve injury-induced allodynia .

PA-8 1 Publications Verification	PACAP Receptor	Neurological Disease Inflammation/Immunology
PA-8 is a potent, selective and orally active PACAP type I (PAC1) receptor antagonist. PA-8 inhibits the phosphorylation of CREB induced by PACAP in *PAC1-, but not VPAC1- or VPAC2-receptor. PA-8 also inhibits PACAP-induced cAMP elevation with an IC₅₀* of 2 nM .

Zelminemab AMG-301	Adenylate Cyclase	Neurological Disease
Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor .

PACAP (1-27), human, ovine, rat 2 Publications Verification PACAP 1-27	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat *PAC1, rat VPAC1* and human VPAC2, respectively .

PACAP (1-27), human, ovine, rat TFA 2 Publications Verification PACAP 1-27 TFA	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat *PAC1, rat VPAC1* and human VPAC2, respectively .

PA-9	PACAP Receptor	Neurological Disease Inflammation/Immunology
PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC₅₀ of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain .

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a **PAC₁ receptor** activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research .

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a **PAC₁ receptor** activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research .

Maxadilan	PACAP Receptor Caspase Apoptosis PKA Interleukin Related TNF Receptor	Cardiovascular Disease Neurological Disease
Maxadilan is a specific irreversible *PAC1* receptor agonist and a potent vasodilator peptide present in the salivary glands of sand flies. Maxadilan exhibits anti-apoptotic activity in hADSCs. Maxadilan inhibits pro-inflammatory cytokines (TNF-α) and enhances anti-inflammatory mediators (IL-10). Maxadilan can activate leukocytes and inhibit vascular permeability through PAC1 receptors. Maxadilan promotes neural differentiation of human adipose-derived stem cells. Maxadilan can be used to study endotoxin shock, atherosclerosis, and neurodegenerative diseases ^{[1] [2] [3] [4] [5]}.

ALD1910	PACAP Receptor	Neurological Disease
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .

Cat. No.	Product Name	Target	Research Area

PACAP (1-27), human, ovine, rat 2 Publications Verification PACAP 1-27	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat *PAC1, rat VPAC1* and human VPAC2, respectively .

PACAP (1-27), human, ovine, rat TFA 2 Publications Verification PACAP 1-27 TFA	PACAP Receptor	Neurological Disease Metabolic Disease
PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC₅₀s of 3 nM, 2 nM and 5 nM for rat *PAC1, rat VPAC1* and human VPAC2, respectively .

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a **PAC₁ receptor** activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research .

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a **PAC₁ receptor** activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research .

Maxadilan	PACAP Receptor Caspase Apoptosis PKA Interleukin Related TNF Receptor	Cardiovascular Disease Neurological Disease
Maxadilan is a specific irreversible *PAC1* receptor agonist and a potent vasodilator peptide present in the salivary glands of sand flies. Maxadilan exhibits anti-apoptotic activity in hADSCs. Maxadilan inhibits pro-inflammatory cytokines (TNF-α) and enhances anti-inflammatory mediators (IL-10). Maxadilan can activate leukocytes and inhibit vascular permeability through PAC1 receptors. Maxadilan promotes neural differentiation of human adipose-derived stem cells. Maxadilan can be used to study endotoxin shock, atherosclerosis, and neurodegenerative diseases ^{[1] [2] [3] [4] [5]}.

Cat. No.	Product Name	Target	Research Area

Zelminemab AMG-301	Adenylate Cyclase	Neurological Disease
Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor .

ALD1910	PACAP Receptor	Neurological Disease
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator; DNA/RNA sequence conversion tools

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2025 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us